RonaldTakeshiMitsuyasuMD

Grant Support

• AIDS Malignancy Clinical Trials Consortium (AMC)National Cancer Institute2010–2012
• South American Prevention Of HIV Research Training Program (SAPHIR)National Institute Of Mental Health2011
• Ucla-Usc Combined LOS Angeles Core SiteNational Cancer Institute2010–2011
• Network Core Research LABNational Cancer Institute2010–2011
• AMC Group Chairman, University Of California, LANational Cancer Institute2010–2011
• A Prospective Phase II Study Of A High DOSE, Short Course Regimen (R-Codox-M/IvaNational Center For Research Resources2010
• A Phase II Trial Of Doxil, Rituximab, Cyclophosphamide, Vincristine, And PrednisNational Center For Research Resources2010
• A Phase II Trial Of Combined Modality Therapy PLUS Cetuximab In Hiv-Associated ANational Center For Research Resources2010
• Phase IIA Trial Of 1% Topical Cidofovir For Treatment Of High-Grade Perianal SquNational Center For Research Resources2009–2010
• A Single Arm, Open-Label Pilot Trial Of The Safety And Immunogenicity Of A QuadrNational Center For Research Resources2009–2010
• Short Course Regimen (R-Codox-M/Ivac) INational Center For Research Resources2009
• Double-Blind Phase II Study Of Multiple Doses Of Palifermin (RHUKGF) For AIDSNational Center For Research Resources2009
• A Phase II Trial Of Doxil, Rituximab, Cyclophosphamide,National Center For Research Resources2009
• AIDS Malignancy Clinical Trials ConsortiumNational Cancer Institute2006–2009
• A Phase II Trial Of Imatinib Mesylate (GLEEVEC) In Patients With HIV RelatedNational Center For Research Resources2007–2008
• AMC 036: A Phase II Trial Of Topical Halofuginone In Patients With HIV RelatNational Center For Research Resources2006–2008
• A Phase II Double-Blind, Randomized, Placebo-Controlled Study To Evaluate TheNational Center For Research Resources2006–2008
• Recruitment And RetentionNational Cancer Institute2006
• Group Chair Administrative Office &Overview Of Entire ApplicationNational Cancer Institute2006
• Funding PLAN AdditionsNational Cancer Institute2006
• Discretionary FundingNational Cancer Institute2006
• Improving Immune Reconstruction With Growth Hormone In Hiv-Infected SubjectsNational Center For Research Resources2005–2006
• Randomized Trial Of Standard Chemotherapy With Or Without The Addition Of Ritux)National Center For Research Resources2005
• A Randomized Phase I/II Pilot Study Of Intermittent Withdrawal Of AntiretroviNational Center For Research Resources2005
• Aids-Associated Malignancies Clinical Trials ConsortiumNational Cancer Institute2003–2005
• Rituxan For Treatment Of Hiv-Associated Non-Hodgkin'S LYNational Center For Research Resources2004
• Improving Immune Reconstruction With Growth Hormone In Hiv-Infected Subjects...National Center For Research Resources2004
• Exploratory, Open-Label, Randomized Trial To EvaluateNational Center For Research Resources2004
• AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1994–2003
• Phase I Trial Of Antitumor Activity Of Inf AlphaNational Center For Research Resources2001
• Phase II Study Of Autologous CD4 Zeta Gene Modified T Cells In HIVNational Center For Research Resources1999–2001
• Comparison Study Of Liposomal Doxorubicin To Treat AIDS Kaposi'S SarcomaNational Center For Research Resources1999–2001
• Autologous CD4 Zeta Gene Modified T Cells In HIV Infected PatientsNational Center For Research Resources1999–2001
• Phase II Study Of The Activity And Safety Of Autologus Cd4-Zeta Gene-ModifiedNational Center For Research Resources1998–2001
• Phase II Study Of Intermittent Recombinant Human Interleukin-2 By IntravenouslyNational Center For Research Resources1998–2001
• Phase I Trial Of CD34+ Stem Cells Transduced With An HIV RibozymeNational Center For Research Resources1998–2001
• Phase III Study Of Indinavir (IDV) With Zidovudine (ZDV) And Lamivudine (3TC)National Center For Research Resources1998–1999
• Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
• Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
• Outreach AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
• Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
• Neurology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
• Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
• HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
• Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases1996–1999
• Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
• Study Of Continuous Infusion Or Subcutaneously Administered ProleukinNational Center For Research Resources1996–1999
• Continuous Infusion Proleukin (ALDESLEUKIN) Chiron Recombinant InterleukinNational Center For Research Resources1995–1999
• Comparison Study Of Liposomal Doxorubicin With/Without Bleomycin And VincristineNational Center For Research Resources1998
• Phase II Study Of Indinavir (IDV) With Zidovudine (ZDV) And Lamivudine (3TC)National Center For Research Resources1997
• Open, Non-Comparative Phase II Study Of Topotecan As A Continuous DoseNational Center For Research Resources1996–1997
• Combination Vincristine And DDI In AIDS Related Kaposi'S SarcomaNational Center For Research Resources1996–1997
• HIV-1 Derived Immunogens In Infected Individuals With >500 CD4 Cells/Cubic MMNational Center For Research Resources1995–1997
• Comparison Of Safety And Activity Of HIV-1 Vaccine With PlaceboNational Center For Research Resources1995–1997
• AIDS Associated Malignancies Clinical Trials ConsortiumNational Cancer Institute1995–1997
• Study Of MN Rgp120/Hiv-1 In HIV Infected Patients With 50-500 C4 Cells/Cubic MMNational Center For Research Resources1995–1996
• Monotherapy VS Combination Therapy With Nucleoside Analogs In HIV PatientsNational Center For Research Resources1995–1996
• Extended Immunization With MN Rgp120/Hiv-1 VaccineNational Center For Research Resources1995–1996
• Dose Escalating Safety And Tolerance Study Of Scd4-Pe40 In HIV PatientsNational Center For Research Resources1995–1996
• Safety And Efficacy Of Zidovudine For Asymptomatic HIV Infected PeopleNational Center For Research Resources1995
• Phase II Study Of CD8+ T Cells Infused With Recombinant Interleukin-2National Center For Research Resources1995
• Combination Vincristine And DDI Or DDC In AIDS Related Kaposi'S SarcomaNational Center For Research Resources1995
• Adult AIDS Clinical ResearchNational Institute Of Allergy And Infectious Diseases1994–1995
• Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1992–1993
• AIDS Institutional TrainingNational Institute Of Allergy And Infectious Diseases1990–1992
• AIDS Clinical Trials Group Conversion From AteuNational Institute Of Allergy And Infectious Diseases1990–1991
• Physician-Investigator Development Award ProgramNational Cancer Institute1985–1986
• Prevention Of Graft-Vs-Host DiseaseNational Cancer Institute1985